Sheng Chen

Dr. Sheng Chen


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Progress in Neurobiology
Verified
Journal Article
Closed access
SCSheng Chen
Sheng Chen
HFHua Feng
Hua Feng
PSPrativa Sherchan
Prativa Sherchan
DKDamon Klebe
Damon Klebe
GZGang Zhao
Gang Zhao
JZJohn Zhang
John Zhang

23 November 2013 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
QMQingyi Ma
Qingyi Ma
SCSheng Chen
Sheng Chen
QHQin Hu
Qin Hu
HFHua Feng
Hua Feng
JZJohn Zhang
John Zhang
JTJiping Tang
Jiping Tang

23 December 2014 in Translational Stroke Research
Verified
Journal Article
Closed access
PDF file
SCSheng Chen
Sheng Chen
QYQingwu Yang
Qingwu Yang
GCGao Chen
Gao Chen
JZJohn H. Zhang
John H. Zhang

1 January 2016 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
KZKeren Zhou
Keren Zhou
LSLigen Shi
Ligen Shi
YWYan Wang
Yan Wang
SCSheng Chen
Sheng Chen
JZJianmin Zhang
Jianmin Zhang
Inflammasomes are multiprotein complexes that trigger the activation of caspases-1 and subsequently the maturation of proinflammatory cytokines interleukin-1βand interleukin-18. These cytokines play a critical role in mediating inflammation and innate immunity response. Among various inflammasome complexes, the NLRP3 inflammasome is the best characterized, which has been demonstrated as a crucial role in various diseases. Here, we review recently described mechanisms that are involved in the activation and regulation of NLRP3 inflammasome. In addition, we summarize the recent researches on the role of NLRP3 inflammasome in central nervous system (CNS) diseases, including traumatic brain injury, ischemic stroke and hemorrhagic stroke, brain tumor, neurodegenerative diseases, and other CNS diseases. In conclusion, the NLRP3 inflammasome may be a promising therapeutic target for these CNS diseases.

1 January 2017 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SCSheng Chen
Sheng Chen
JLJinqi Luo
Jinqi Luo
CRCesar Reis
Cesar Reis
AMAnatol Manaenko
Anatol Manaenko
JZJianming Zhang
Jianming Zhang
Hydrocephalus (HCP) is a common complication in patients with subarachnoid hemorrhage. In this review, we summarize the advanced research on HCP and discuss the understanding of the molecular originators of HCP and the development of diagnoses and remedies of HCP after SAH. It has been reported that inflammation, apoptosis, autophagy, and oxidative stress are the important causes of HCP, and well-known molecules including transforming growth factor, matrix metalloproteinases, and iron terminally lead to fibrosis and blockage of HCP. Potential medicines for HCP are still in preclinical status, and surgery is the most prevalent and efficient therapy, despite respective risks of different surgical methods, including lamina terminalis fenestration, ventricle-peritoneal shunting, and lumbar-peritoneal shunting. HCP remains an ailment that cannot be ignored and even with various solutions the medical community is still trying to understand and settle why and how it develops and accordingly improve the prognosis of these patients with HCP.

1 October 2013 in Neurobiology of Disease
Verified
Journal Article
Closed access
SCSheng Chen
Sheng Chen
QMQingyi Ma
Qingyi Ma
PKPaul R. Krafft
Paul R. Krafft
QHQin Hu
Qin Hu
WRWilliam Rolland
William Rolland
JZJohn Zhang
John Zhang